Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Determine which no fee travel card is better suited for you. Make the right choice for your travel goals and preferences.
22,600 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
As AI buzz grows, blockbuster stocks are priced to perfection. This article explores a contrarian AI stock idea that ...
Offerpad rolls out two internal AI platforms, SCOUT and HENRY, as the company pursues 1,000 quarterly home transactio...
Robinhood launches a controlled beta of its new Social feature, inviting a small group of users to follow traders, di...
Atlantic Avenue Mortgage tops January HECM broker endorsements, signaling strong demand for senior home equity even a...
Former BitMEX chief Arthur Hayes reportedly acquired a tranche of ETHFI ahead of Upbit's listing, sparking a price sp...
Rivian shares surged about 8% after the company unveiled the R2 midsize SUV, signaling a push toward broader market a...
Digital land once valued like scarcity-backed cities now trades at floor-level levels. The slump spans Sandbox, Decen...
New York’s upstart candidate Jack Schlossberg argues JFK would be alarmed by America’s global standing, while acknowl...
Bitcoin has fallen out of step with broad money growth, creating a large gap between its price and M2-derived fair va...
A sharp one-week drop surprised many investors. This analysis explains the drivers behind the decline, from KPI discl...
Geopolitics are shaping energy markets in real time. A fresh disruption from Iran adds a new layer of risk and opport...